Search

Your search keyword '"DEL GIUDICE, Ilaria"' showing total 511 results
Start Over Author "DEL GIUDICE, Ilaria"
511 results on '"DEL GIUDICE, Ilaria"'

2. Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial

Author

Pulsoni, Alessandro, Ferrero, Simone, Tosti, Maria Elena, Luminari, Stefano, Dondi, Alessandra, Cavallo, Federica, Merli, Francesco, Liberati, Anna Marina, Cenfra, Natalia, Renzi, Daniela, Zanni, Manuela, Boccomini, Carola, Ferreri, Andrés J M, Rattotti, Sara, Zilioli, Vittorio Ruggero, Bolis, Silvia Anna, Bernuzzi, Patrizia, Musuraca, Gerardo, Gaidano, Gianluca, Perrone, Tommasina, Stelitano, Caterina, Tucci, Alessandra, Corradini, Paolo, Bigliardi, Sara, Re, Francesca, Cencini, Emanuele, Mannarella, Clara, Mannina, Donato, Celli, Melania, Tani, Monica, Annechini, Giorgia, Assanto, Giovanni Manfredi, Grapulin, Lavinia, Guarini, Anna, Cavalli, Marzia, De Novi, Lucia Anna, Bomben, Riccardo, Ciabatti, Elena, Genuardi, Elisa, Drandi, Daniela, Della Starza, Irene, Arcaini, Luca, Ricardi, Umberto, Gattei, Valter, Galimberti, Sara, Ladetto, Marco, Foà, Robin, and Del Giudice, Ilaria

Published
2024
Full Text
View/download PDF

3. Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study.

Author

Giovanni Manfredi Assanto ,, Matteo Totaro, Poggiali Rebecca, Delli Paoli Adele, Annechini Giorgia, D’Elia Gianna Maria, Aji Francesco, Petrucci Luigi, Fazio Francesca, Del Giudice Ilaria, Martelli Maurizio, Micozzi Alessandra, and Giuseppe Gentile

Subjects
B-cell malignancies, COVID-19, tixagevimab-cilgavimab, Pre-exposure prophylaxis, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Severe Acute Respiratory Syndrome CoronaVirus‐2 (SARS‐CoV‐2) infection can result in different clinical manifestations (COVID-19), starting from asymptomatic disease to life threatening respiratory insufficiency. Onco-haematologic patients are at higher risk to develop severe COVID-19. In particular, patients affected by lymphoproliferative diseases, given the impaired cell-mediated and antibody-mediated immunity and treatment toxicity, develop more often a symptomatic and a more serious disease of Covid-19. Various therapeutic and prophylactic agents are being used against COVID‐19 such as antiviral drugs, vaccines and antiviral S‐protein monoclonal antibodies. Pre-exposure prophylaxis with AZD442/Evusheld (tixagevimab-cilgavimab) may be a complementary strategy to decrease the incidence or severity of COVID-19 for patients with B-cell malignancies. Tixagevimab-cilgavimab is a combination of two monoclonal antibodies that bind SARS-CoV-2 spike protein and inhibits the attachment to the surface of cells, preventing viral entry in the cell and COVID-19 development. In the setting of hematology real-life, few data are available on the impact of pre-exposure prophylaxis, given the multiple factors involved in the clinical behavior of SARS-CoV-2 . Our aim was to evaluate the clinical benefit and the safety of this strategy at our center.

Published
2023
Full Text
View/download PDF

5. Local Radiotherapy and MRD-Driven Immunotherapy in Early-Stage Follicular Lymphoma: Final Results of the FIL - 'MIRO' Multicenter Phase II Trial

Author

Pulsoni, Alessandro, primary, Ferrero, Simone, additional, Tosti, Maria Elena, additional, Luminari, Stefano, additional, Dondi, Alessandra, additional, Cavallo, Federica, additional, Merli, Francesco, additional, Liberati, Anna Marina, additional, Cenfra, Natalia, additional, Renzi, Daniela, additional, Zanni, Manuela, additional, Boccomini, Carola, additional, Ferreri, Andrés, additional, Rattotti, Sara, additional, Zilioli, Vittorio Ruggero, additional, Bolis, Silvia Anna, additional, Bernuzzi, Patrizia, additional, Musuraca, Gerardo, additional, Gaidano, Gianluca, additional, Perrone, Tommasina, additional, Stelitano, Caterina, additional, Tucci, Alessandra, additional, Corradini, Paolo, additional, Bigliardi, Sara, additional, Re, Francesca, additional, Cencini, Emanuele, additional, Mannarella, Clara, additional, Mannina, Donato, additional, Celli, Melania, additional, Tani, Monica, additional, Annechini, Giorgia, additional, Assanto, Giovanni Manfredi, additional, Grapulin, Lavinia, additional, Guarini, Anna, additional, Cavalli, Marzia, additional, De Novi, Lucia Anna, additional, Bomben, Riccardo, additional, Ciabatti, Elena, additional, Genuardi, Elisa, additional, Drandi, Daniela, additional, Della Starza, Irene, additional, Arcaini, Luca, additional, Ricardi, Umberto, additional, Gattei, Valter, additional, Galimberti, Sara, additional, Ladetto, Marco, additional, Foà, Robin, additional, and del Giudice, Ilaria, additional

Published
2024
Full Text
View/download PDF

6. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Author

Gentile, Massimo, Morabito, Fortunato, Del Poeta, Giovanni, Mauro, Francesca Romana, Reda, Gianluigi, Sportoletti, Paolo, Laurenti, Luca, Coscia, Marta, Herishanu, Yair, Recchia, Anna Grazia, Varettoni, Marzia, Murru, Roberta, Chiarenza, Annalisa, Condoluci, Adalgisa, Moia, Riccardo, Pietrasanta, Daniela, Loseto, Giacomo, Consoli, Ugo, Scortechini, Ilaria, Rossi, Francesca Maria, Zucchetto, Antonella, Fraticelli, Vincenzo, Vigna, Ernesto, Botta, Cirino, Tripepi, Giovanni, Arrigo, Graziella D’, Rago, Angela, Angeletti, Ilaria, Biagi, Annalisa, Del Giudice, Ilaria, Bomben, Riccardo, Rigolin, Gian Matteo, Rossi, Davide, Di Raimondo, Francesco, Gaidano, Gianluca, Polliack, Aaron, Cuneo, Antonio, Foà, Robin, and Gattei, Valter

Published
2021
Full Text
View/download PDF

7. The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia

Author

Visentin, Andrea, Bonaldi, Laura, Rigolin, Gian Matteo, Mauro, Francesca Romana, Martines, Annalisa, Frezzato, Federica, Imbergamo, Silvia, Scomazzon, Edoardo, Pravato, Stefano, Bardi, Maria Antonella, Cavallari, Maurizio, Volta, Eleonora, Cavazzini, Francesco, Nanni, Maurizio, Del Giudice, Ilaria, Facco, Monica, Guarini, Anna, Semenzato, Gianpietro, Foà, Robin, Cuneo, Antonio, and Trentin, Livio

Published
2019
Full Text
View/download PDF

8. XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling

Author

Moia, Riccardo, primary, Terzi di Bergamo, Lodovico, additional, Talotta, Donatella, additional, Bomben, Riccardo, additional, Forestieri, Gabriela, additional, Spina, Valeria, additional, Bruscaggin, Alessio, additional, Cosentino, Chiara, additional, Almasri, Mohammad, additional, Dondolin, Riccardo, additional, Bittolo, Tamara, additional, Zucchetto, Antonella, additional, Baldoni, Stefano, additional, Del Giudice, Ilaria, additional, Mauro, Francesca Romana, additional, Maffei, Rossana, additional, Chiarenza, Annalisa, additional, Tafuri, Agostino, additional, Laureana, Roberta, additional, Del Principe, Maria Ilaria, additional, Zaja, Francesco, additional, D'Arena, Giovanni, additional, Olivieri, Jacopo, additional, Rasi, Silvia, additional, Mahmoud, Abdurraouf, additional, Al Essa, Wael, additional, Awikeh, Bassel, additional, Kogila, Sreekar, additional, Bellia, Matteo, additional, Mouhssine, Samir, additional, Sportoletti, Paolo, additional, Marasca, Roberto, additional, Scarfò, Lydia, additional, Ghia, Paolo, additional, Gattei, Valter, additional, Foà, Robin, additional, Rossi, Davide, additional, and Gaidano, Gianluca, additional

Published
2023
Full Text
View/download PDF

9. S219: PREDICTING THROMBOTIC RISK IN PATIENTS WITH HODGKIN LYMPHOMA: A MULTICENTRIC STUDY OF THROLY AND KHORANA RISK SCORES

Author

Assanto, Giovanni Manfredi, primary, Salvatori, Martina, additional, Pontecorvo, Sara, additional, Maiorana, Gianluca, additional, Cenfra, Natalia, additional, D’elia, Gianna Maria, additional, Bianchi, Maria Paola, additional, Annechini, Giorgia, additional, Santoro, Cristina Santoro, additional, Martelli, Maurizio, additional, Tafuri, Agostino, additional, Pulsoni, Alessandro, additional, Del Giudice, Ilaria, additional, and Chistolini, Antonio, additional

Published
2023
Full Text
View/download PDF

10. P1232: NON-INVASIVE MINIMAL RESIDUAL DISEASE ANALYSIS BY IMMUNOGLOBULIN GENE REARRANGEMENTS ON CIRCULATING TUMOR DNA PREDICTS THE OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

Author

Soscia, Roberta, primary, Manfredi Assanto, Giovanni, additional, Della Starza, Irene, additional, Moia, Riccardo, additional, Talotta, Donatella, additional, Bellomarino, Vittorio, additional, Bellissimo, Teresa, additional, Rocco, Alice DI, additional, Petrucci, Luigi, additional, Martelli, Maurizio, additional, Rita Guarini, Anna, additional, Gaidano, Gianluca, additional, Foà, Robin, additional, and Del Giudice, Ilaria, additional

Published
2023
Full Text
View/download PDF

11. P597: XPO1 MUTATIONS IDENTIFY EARLY STAGE CLL CHARACTERIZED BY SHORTER TIME TO FIRST TREATMENT AND ENHANCED BCR SIGNALING

Author

Talotta, Donatella, primary, Moia, Riccardo, additional, Terzi DI Bergamo, Lodovico, additional, Bomben, Riccardo, additional, Forestieri, Gabriela, additional, Spina, Valeria, additional, Bruscaggin, Alessio, additional, Cosentino, Chiara, additional, Almasri, Mohammad, additional, Dondolin, Riccardo, additional, Bittolo, Tamara, additional, Zucchetto, Antonella, additional, Baldoni, Stefano, additional, Del Giudice, Ilaria, additional, Romana Mauro, Francesca, additional, Maffei, Rossana, additional, Chiarenza, Annalisa, additional, Tafuri, Agostino, additional, Laureana, Roberta, additional, Ilaria Del Principe, Maria, additional, Zaja, Francesco, additional, D’arena, Giovanni, additional, Olivieri, Jacopo, additional, Rasi, Silvia, additional, Mahmoud, Abdurraouf, additional, Al Essa, Wael, additional, Awikeh, Bassel, additional, Kogila, Sreekar, additional, Bellia, Matteo, additional, Mouhssine, Samir, additional, Sportoletti, Paolo, additional, Marasca, Roberto, additional, Scarfò, Lydia, additional, Ghia, Paolo, additional, Gattei, Valter, additional, Foà, Robin, additional, Rossi, Davide, additional, and Gaidano, Gianluca, additional

Published
2023
Full Text
View/download PDF

12. Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi

Author

Gotti, Manuel, primary, Sciarra, Roberta, additional, Pulsoni, Alessandro, additional, Merli, Francesco, additional, Luminari, Stefano, additional, Zerbi, Caterina, additional, Trentin, Livio, additional, Re, Alessandro, additional, Rusconi, Chiara, additional, Viviani, Simonetta, additional, Rossi, Andrea, additional, Cocito, Federica, additional, Botto, Barbara, additional, Meli, Erika, additional, Pinto, Antonello, additional, Dogliotti, Irene, additional, Gini, Guido, additional, Puccini, Benedetta, additional, Ricci, Francesca, additional, Nassi, Luca, additional, Fabbri, Alberto, additional, Liberati, Anna Marina, additional, Merli, Michele, additional, Filippi, Andrea Riccardo, additional, Bonfichi, Maurizio, additional, Zoboli, Valentina, additional, Tartaglia, Germana, additional, Annechini, Giorgia, additional, D’Elia, Gianna Maria, additional, Del Giudice, Ilaria, additional, Alvarez, Isabel, additional, Visentin, Andrea, additional, Pravato, Stefano, additional, Dalceggio, Daniela, additional, Pagani, Chiara, additional, Ferrari, Silvia, additional, Cristinelli, Caterina, additional, Lazic, Tanja, additional, Ferretti, Virginia Valeria, additional, Ricardi, Umberto, additional, and Arcaini, Luca, additional

Published
2023
Full Text
View/download PDF

13. Additional Table I from Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial

Author

Galimberti, Sara, primary, Luminari, Stefano, primary, Ciabatti, Elena, primary, Grassi, Susanna, primary, Guerrini, Francesca, primary, Dondi, Alessandra, primary, Marcheselli, Luigi, primary, Ladetto, Marco, primary, Piccaluga, Pier Paolo, primary, Gazzola, Anna, primary, Mannu, Claudia, primary, Monitillo, Luigia, primary, Mantoan, Barbara, primary, Del Giudice, Ilaria, primary, Della Starza, Irene, primary, Cavalli, Marzia, primary, Arcaini, Luca, primary, Tucci, Alessandra, primary, Palumbo, Giuseppe Alberto, primary, Rigacci, Luigi, primary, Pulsoni, Alessandro, primary, Vitolo, Umberto, primary, Boccomini, Carola, primary, Vallisa, Daniele, primary, Bertoldero, Giovanni, primary, Gaidano, Gianluca, primary, Musto, Pellegrino, primary, Petrini, Mario, primary, and Federico, Massimo, primary

Published
2023
Full Text
View/download PDF

14. Supplemental Figure Legend from Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial

Author

Galimberti, Sara, primary, Luminari, Stefano, primary, Ciabatti, Elena, primary, Grassi, Susanna, primary, Guerrini, Francesca, primary, Dondi, Alessandra, primary, Marcheselli, Luigi, primary, Ladetto, Marco, primary, Piccaluga, Pier Paolo, primary, Gazzola, Anna, primary, Mannu, Claudia, primary, Monitillo, Luigia, primary, Mantoan, Barbara, primary, Del Giudice, Ilaria, primary, Della Starza, Irene, primary, Cavalli, Marzia, primary, Arcaini, Luca, primary, Tucci, Alessandra, primary, Palumbo, Giuseppe Alberto, primary, Rigacci, Luigi, primary, Pulsoni, Alessandro, primary, Vitolo, Umberto, primary, Boccomini, Carola, primary, Vallisa, Daniele, primary, Bertoldero, Giovanni, primary, Gaidano, Gianluca, primary, Musto, Pellegrino, primary, Petrini, Mario, primary, and Federico, Massimo, primary

Published
2023
Full Text
View/download PDF

15. Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?

Author

Assanto, Giovanni Manfredi, primary, Del Giudice, Ilaria, additional, Della Starza, Irene, additional, Soscia, Roberta, additional, Cavalli, Marzia, additional, Cola, Mattia, additional, Bellomarino, Vittorio, additional, Di Trani, Mariangela, additional, Guarini, Anna, additional, and Foà, Robin, additional

Published
2023
Full Text
View/download PDF

16. Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature

Author

Del Giudice, Ilaria, Cappelli, Luca Vincenzo, Delgado, Julio, Niemann, Carsten Utoft, Andersen, Michael Asger, Rotbain, Emelie Hamotal Curovic, Aarup, Kathrine, Walewska, Renata, Visentin, Andrea, Deodato, Marina, Frustaci, Anna Maria, Cavalloni, Chiara, Gentile, Massimo, Yassin, Mohamed A., Lad, Deepesh, Scarfo, Lydia, Flogegard, Max, Mattsson, Mattias, Raponi, Sara, Ilari, Caterina, Starza, Irene Della, Orlandi, Ester M., Tedeschi, Alessandra, Trentin, Livio, Semenzato, Gianpietro, Guarini, Anna, Ghia, Paolo, Montserrat, Emili, Foa, Robin, Del Giudice, Ilaria, Cappelli, Luca Vincenzo, Delgado, Julio, Niemann, Carsten Utoft, Andersen, Michael Asger, Rotbain, Emelie Hamotal Curovic, Aarup, Kathrine, Walewska, Renata, Visentin, Andrea, Deodato, Marina, Frustaci, Anna Maria, Cavalloni, Chiara, Gentile, Massimo, Yassin, Mohamed A., Lad, Deepesh, Scarfo, Lydia, Flogegard, Max, Mattsson, Mattias, Raponi, Sara, Ilari, Caterina, Starza, Irene Della, Orlandi, Ester M., Tedeschi, Alessandra, Trentin, Livio, Semenzato, Gianpietro, Guarini, Anna, Ghia, Paolo, Montserrat, Emili, and Foa, Robin

Published
2023
Full Text
View/download PDF

17. High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the GIMEMA phase II LLC1518 - 'Veritas' study

Author

Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, Laurenti, Luca (ORCID:0000-0002-8327-1396), Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

The GIMEMA phase II LLC1518 VERITAS trial investigated the efficacy and safety of frontline, fixed-duration venetoclax and rituximab (VenR) combination in young (≤65 years) and fit patients with chronic lymphocytic leukemia (CLL) and unmutated IGHV and/or TP53 disruption. Treatment consisted of the Ven ramp-up, six-monthly courses of the VenR combination, followed by six monthly courses of Ven single agent. A centralized assessment of measurable minimal residual disease (MRD) was performed on the peripheral blood (PB) and bone marrow (BM) by ASO-PCR at the end of treatment (EOT) and during the follow-up. The primary endpoint was the complete remission (CR) rate at the EOT. Seventy-five patients were enrolled; the median age was 54 years (range 38-65), 96% had unmutated IGHV, 9 (12%) had TP53 disruption, and 4% were IGHV mutated with TP53 disruption. The overall response rate (ORR) at the EOT was 94.7%, with a CR rate of 76%. An undetectable (u) MRD was recorded in 69.3% of patients in the PB and 58.7% in the BM. The 12-month MRD-free survival in the 52 patients with uMRD in the PB at the EOT was 73.1%. After a median follow-up of 20.8 months, no disease progressions were observed. Three patients have died, two due to Covid-19 and 1 to tumor lysis syndrome. The first report of the VERITAS study shows that frontline VenR was associated with a high rate of CRs and durable responses with uMRD in young patients with CLL and unfavorable genetic characteristics.

Published
2023

18. Additional lesions identified by genomic microarrays are associated with an inferior outcome in low‐risk chronic lymphocytic leukaemia patients.

Author

Rigolin, Gian Matteo, Traversa, Alice, Caputo, Viviana, Del Giudice, Ilaria, Bardi, Antonella, Saccenti, Elena, Raponi, Sara, Ilari, Caterina, Cafforio, Luciana, Giovannetti, Agnese, Pizzuti, Antonio, Guarini, Anna, Foà, Robin, and Cuneo, Antonio

Subjects
LYMPHOCYTIC leukemia, FLUORESCENCE in situ hybridization, CHRONIC leukemia, CHRONIC lymphocytic leukemia
Abstract

Summary: We explored the relevance of genomic microarrays (GM) in the refinement of prognosis in newly diagnosed low‐risk chronic lymphocytic leukaemia (CLL) patients as defined by isolated del(13q) or no lesions by a standard 4 probe fluorescence in situ hybridization (FISH) analysis. Compared to FISH, additional lesions were detected by GM in 27 of the 119 patients (22.7%). The concordance rate between FISH and GM was 87.4%. Discordant results between cytogenetic banding analysis (CBA) and GM were observed in 45/119 cases (37.8%) and were mainly due to the intrinsic characteristics of each technique. The presence of additional lesions by GM was associated with age > 65 years (p = 0.047), advanced Binet stage (p = 0.001), CLL‐IPI score (p < 0.001), a complex karyotype (p = 0.004) and a worse time‐to‐first treatment in multivariate analysis (p = 0.009). Additional lesions by GM were also significantly associated with a worse time‐to‐first treatment in the subset of patients with wild‐type TP53 and mutated IGHV (p = 0.025). In CLL patients with low‐risk features, the presence of additional lesions identified by GM helps to identify a subset of patients with a worse outcome that could be proposed for a risk‐adapted follow‐up and for early treatment including targeted agents within clinical trials. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature

Author

Del Giudice, Ilaria, primary, Cappelli, Luca Vincenzo, additional, Delgado, Julio, additional, Niemann, Carsten Utoft, additional, Andersen, Michael Asger, additional, Rotbain, Emelie Hamotal Curovic, additional, Aarup, Kathrine, additional, Walewska, Renata, additional, Visentin, Andrea, additional, Deodato, Marina, additional, Frustaci, Anna Maria, additional, Cavalloni, Chiara, additional, Gentile, Massimo, additional, Yassin, Mohamed A., additional, Lad, Deepesh, additional, Scarfò, Lydia, additional, Flogegard, Max, additional, Mattsson, Mattias, additional, Raponi, Sara, additional, Ilari, Caterina, additional, Starza, Irene Della, additional, Orlandi, Ester M., additional, Tedeschi, Alessandra, additional, Trentin, Livio, additional, Semenzato, Gianpietro, additional, Guarini, Anna, additional, Ghia, Paolo, additional, Montserrat, Emili, additional, and Foà, Robin, additional

Published
2023
Full Text
View/download PDF

20. Sialylation regulates migration in chronic lymphocytic leukemia

Author

Natoni, Alessandro, primary, Cerreto, Marina, additional, De Propris, Maria Stefania, additional, Del Giudice, Ilaria, additional, Soscia, Roberta, additional, Peragine, Nadia, additional, Intoppa, Stefania, additional, Milani, Maria Laura, additional, Guarini, Anna, additional, and Foà, Robin, additional

Published
2023
Full Text
View/download PDF

21. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study

Author

Mauro, Francesca R., primary, Starza, Irene Della, additional, Messina, Monica, additional, Reda, Gianluigi, additional, Trentin, Livio, additional, Coscia, Marta, additional, Sportoletti, Paolo, additional, Orsucci, Lorella, additional, Arena, Valentina, additional, Casaluci, Gloria Margiotta, additional, Marasca, Roberto, additional, Murru, Roberta, additional, Laurenti, Luca, additional, Ilariucci, Fiorella, additional, Stelitano, Caterina, additional, Mannina, Donato, additional, Massaia, Massimo, additional, Rigolin, Gian Matteo, additional, Scarfò, Lydia, additional, Marchetti, Monia, additional, Levato, Luciano, additional, Tani, Monica, additional, Arcari, Annalisa, additional, Musuraca, Gerardo, additional, Deodato, Marina, additional, Galieni, Piero, additional, Patrizi, Valeria Belsito, additional, Gottardi, Daniela, additional, Liberati, Anna Marina, additional, Giordano, Annamaria, additional, Molinari, Maria Chiara, additional, Pietrasanta, Daniela, additional, Mattiello, Veronica, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Albano, Francesco, additional, Neri, Antonino, additional, De Novi, Lucia Anna, additional, De Propris, Maria Stefania, additional, Nanni, Mauro, additional, Del Giudice, Ilaria, additional, Guarini, Anna, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Piciocchi, Alfonso, additional, Cuneo, Antonio, additional, and Foà, Robin, additional

Published
2023
Full Text
View/download PDF

22. Impact of anti‐SARS‐CoV‐2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study

Author

Assanto, Giovanni Manfredi, primary, Di Rocco, Alice, additional, Malfona, Francesco, additional, Capriata, Marcello, additional, Del Giudice, Ilaria, additional, Petrucci, Luigi, additional, Girardi, Paola, additional, D’Elia, Gianna Maria, additional, Martelli, Maurizio, additional, Gentile, Giuseppe, additional, Micozzi, Alessandra, additional, and Pulsoni, Alessandro, additional

Published
2022
Full Text
View/download PDF

23. Venous Thromboembolism (VTE) in Patients with Hodgkin Lymphoma: Retrospective Evaluation of Throly and Khorana Risk Scores

Author

Assanto, Giovanni Manfredi, primary, Salvatori, Martina, additional, Pontecorvo, Sara, additional, Cenfra, Natalia, additional, D'elia, Gianna Maria, additional, Annechini, Giorgia, additional, Martelli, Maurizio, additional, Pulsoni, Alessandro, additional, Del Giudice, Ilaria, additional, and Chistolini, Antonio, additional

Published
2022
Full Text
View/download PDF

24. Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients

Author

Moia, Riccardo, primary, Favini, Chiara, additional, Talotta, Donatella, additional, Dondolin, Riccardo, additional, Almasry, Mohammad, additional, Bruna, Riccardo, additional, Mouhssine, Samir, additional, Della Starza, Irene, additional, Soscia, Roberta, additional, Bruscaggin, Alessio, additional, Terzi Di Bergamo, Lodovico, additional, Andorno, Annalisa, additional, Mercalli, Francesca, additional, Mahmoud, Abdurraouf Mokhtar, additional, Deambrogi, Clara, additional, Rasi, Silvia, additional, Petrucci, Luigi, additional, Bellissimo, Teresa, additional, Boldorini, Renzo, additional, Di Rocco, Alice, additional, Del Giudice, Ilaria, additional, Martelli, Maurizio, additional, Gattei, Valter, additional, Rossi, Davide, additional, Foa, Robin, additional, and Gaidano, Gianluca, additional

Published
2022
Full Text
View/download PDF

25. Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases

Author

Soscia, Roberta, primary, Della Starza, Irene, additional, De Novi, Lucia Anna, additional, Ilari, Caterina, additional, Ansuinelli, Michela, additional, Cavalli, Marzia, additional, Bellomarino, Vittorio, additional, Cafforio, Luciana, additional, Di Trani, Mariangela, additional, Cazzaniga, Giovanni, additional, Fazio, Grazia, additional, Santoro, Alessandra, additional, Salemi, Domenico, additional, Spinelli, Orietta, additional, Tosi, Manuela, additional, Terragna, Carolina, additional, Robustelli, Valentina, additional, Bellissimo, Teresa, additional, Colafigli, Gioia, additional, Breccia, Massimo, additional, Chiaretti, Sabina, additional, Di Rocco, Alice, additional, Martelli, Maurizio, additional, Guarini, Anna, additional, Del Giudice, Ilaria, additional, and Foà, Robin, additional

Published
2022
Full Text
View/download PDF

26. Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia

Author

Moia, Riccardo, primary, Dondolin, Riccardo, additional, De Propris, Maria Stefania, additional, Talotta, Donatella, additional, Mouhssine, Samir, additional, Perutelli, Francesca, additional, Reda, Gianluigi, additional, Mattiello, Veronica, additional, Rigolin, Gian Matteo, additional, Motta, Marina, additional, Olivieri, Jacopo, additional, Fanin, Renato, additional, Perbellini, Omar, additional, Ferrarini, Isacco, additional, Mauro, Francesca Romana, additional, Del Giudice, Ilaria, additional, Laurenti, Luca, additional, Tomasso, Annamaria, additional, Gentile, Massimo, additional, Frustaci, Anna Maria, additional, Tedeschi, Alessandra, additional, Gozzetti, Alessandro, additional, Stelitano, Caterina, additional, Visco, Carlo, additional, Moreno, Carol, additional, Forconi, Francesco, additional, Marasca, Roberto, additional, Coscia, Marta, additional, Rossi, Davide, additional, Foà, Robin, additional, and Gaidano, Gianluca, additional

Published
2022
Full Text
View/download PDF

28. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Author

Mauro, Francesca R., Molica, Stefano, Laurenti, Luca, Cortelezzi, Agostino, Carella, Angelo M., Zaja, Francesco, Chiarenza, Annalisa, Angrilli, Francesco, Nobile, Francesco, Marasca, Roberto, Musolino, Caterina, Brugiatelli, Maura, Piciocchi, Alfonso, Vignetti, Marco, Fazi, Paola, Gentile, Giuseppe, De Propris, Maria S., Starza, Irene Della, Marinelli, Marilisa, Chiaretti, Sabina, Del Giudice, Ilaria, Nanni, Mauro, Albano, Francesco, Cuneo, Antonio, Guarini, Anna, and Foà, Robin

Published
2014
Full Text
View/download PDF

29. Impact of anti‐SARS‐CoV‐2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study.

Author

Assanto, Giovanni Manfredi, Di Rocco, Alice, Malfona, Francesco, Capriata, Marcello, Del Giudice, Ilaria, Petrucci, Luigi, Girardi, Paola, D'Elia, Gianna Maria, Martelli, Maurizio, Gentile, Giuseppe, Micozzi, Alessandra, and Pulsoni, Alessandro

Subjects
MONOCLONAL antibodies, COVID-19, LYMPHOMAS, PROGNOSIS, RETROSPECTIVE studies
Abstract

COVID19 in patients affected by lymphoma represents an important challenge because of the higher mortality rate. Anti‐SARS‐CoV‐2 monoclonal antibodies (anti‐S MoAbs) appear promising in this setting. We report a monocentric retrospective study including 176 patients affected by lymphoma which developed SARS‐CoV‐2 infection since the start of COVID19 pandemic. Overall, mortality was 13.1%, with a decreasing trend between first waves to the last wave of pandemic (18.5% vs. 9.4%, p 0.076). Patients receiving anti‐S MoAbs (41.3%) showed inferior mortality rate (overall survival, OS 93.2% vs. 82.7%, p 0.025) with no serious toxicity, reduced documented pneumonia (26% vs. 33%, p 0.005), and reduced need of oxygen support (14.5% vs. 35.7%, p 0.003). Among patients who received 3 doses of vaccine, the employment of anti‐COVID MoAbs showed a trend of superior survival versus those who did not receive Anti‐S MoAbs (OS rates 97.3% vs. 84.2%, p 0.064). On multivariate analysis, active haematological disease (OS 72% (HR 2.49 CI 1.00–6.41), bendamustine exposure (OS 60% HR 4.2 CI 1.69–10.45) and at least one comorbidity (HR 6.53 CI 1.88–22.60) were independent prognostic factors for death. Our study confirms the adverse prognostic role of COVID‐19 in lymphoma patients in presence of active disease, comorbidities and previous exposure to bendamustine. In our experience, anti‐S MoAbs represented a therapeutic option in vaccinated patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia.

Author

Moia, Riccardo, Dondolin, Riccardo, De Propris, Maria Stefania, Talotta, Donatella, Mouhssine, Samir, Perutelli, Francesca, Reda, Gianluigi, Mattiello, Veronica, Rigolin, Gian Matteo, Motta, Marina, Olivieri, Jacopo, Fanin, Renato, Perbellini, Omar, Ferrarini, Isacco, Mauro, Francesca Romana, Del Giudice, Ilaria, Laurenti, Luca, Tomasso, Annamaria, Gentile, Massimo, and Frustaci, Anna Maria

Subjects
CHRONIC lymphocytic leukemia, NUCLEOTIDE sequencing, FLUORESCENCE in situ hybridization, LOW-income countries, CHRONIC leukemia
Abstract

The I EGR2 i gene, coding for a transcription factor that also mediates the I TP53 i dependent apoptotic pathway, was found to be mutated in 3 patients (8.6%), and further stratifies the outcome of low-risk patients. Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. [Extracted from the article]

Published
2023
Full Text
View/download PDF

31. Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response

Author

Peragine, Nadia, primary, De Propris, Maria Stefania, additional, Intoppa, Stefania, additional, Milani, Maria Laura, additional, Mauro, Francesca Romana, additional, Cuneo, Antonio, additional, Rigolin, Gian Matteo, additional, Del Giudice, Ilaria, additional, Foà, Robin, additional, and Guarini, Anna, additional

Published
2022
Full Text
View/download PDF

33. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

Author

Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, Federico, Massimo, Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, and Federico, Massimo

Abstract

PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. METHODS We randomly assigned treatment-naive, advanced-stage, high-tumor burden follicular lymphoma patients to receive standard RM or a response-adapted postinduction approach on the basis of metabolic response and molecular assessment of minimal residual disease (MRD). The experimental arm used three types of postinduction therapies: for complete metabolic response (CMR) and MRD-negative patients, observation; for CMR and MRD-positive (end of induction or follow-up) patients, four doses of rituximab (one per week, maximum three courses) until MRD-negative; and for non-CMR patients, one dose of ibritumomab tiuxetan followed by standard RM. The study was designed as noninferiority trial with progression-free survival (PFS) as the primary end point. RESULTS Overall, 807 patients were randomly assigned. After a median follow-up of 53 months (range, 1-92 months), patients in the standard arm had a significantly better PFS than those in the experimental arm (3-year PFS 86% v 72%; P < .001). The better PFS of the standard versus experimental arm was confirmed in all the study subgroups except non-CMR patients (n =65; P = .274). The 3-year overall survival was 98% (95% CI, 96 to 99) and 97% (95% CI, 95 to 99) in the reference and experimental arms, respectively (P = .238). CONCLUSION A metabolic and molecular response-adapted therapy as assessed in the FOLL12 study was associated with significantly inferior PFS compared with 2-year RM. The better efficacy of standard RM was confirmed in the subgroup analysis and particularly for patients achieving both CMR and MRDnegative.

Published
2022

34. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia

Author

Rossi, Davide, Fangazio, Marco, Rasi, Silvia, Vaisitti, Tiziana, Monti, Sara, Cresta, Stefania, Chiaretti, Sabina, Del Giudice, Ilaria, Fabbri, Giulia, Bruscaggin, Alessio, Spina, Valeria, Deambrogi, Clara, Marinelli, Marilisa, Famà, Rosella, Greco, Mariangela, Daniele, Giulia, Forconi, Francesco, Gattei, Valter, Bertoni, Francesco, Deaglio, Silvia, Pasqualucci, Laura, Guarini, Anna, Dalla-Favera, Riccardo, Foà, Robin, and Gaidano, Gianluca

Published
2012
Full Text
View/download PDF

35. Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall

Author

De Propris, Maria Stefania, primary, Musiu, Paolo, additional, Intoppa, Stefania, additional, Nardacci, Maria Grazia, additional, Pucciarini, Alessandra, additional, Santi, Alessia, additional, Peragine, Nadia, additional, Canichella, Martina, additional, De Luca, Maria Lucia, additional, D'Elia, Gianna Maria, additional, Del Giudice, Ilaria, additional, Pulsoni, Alessandro, additional, Falini, Brunangelo, additional, Guarini, Anna, additional, Martelli, Maurizio, additional, Tiacci, Enrico, additional, and Foà, Robin, additional

Published
2022
Full Text
View/download PDF

36. Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia

Author

Cafforio, Luciana, Raponi, Sara, Cappelli, Luca Vincenzo, Ilari, Caterina, Soscia, Roberta, De Propris, Maria Stefania, Mariglia, Paola, Rigolin, Gian Matteo, Bardi, Antonella, Peragine, Nadia, Piciocchi, Alfonso, Arena, Valentina, Mauro, Francesca Romana, Cuneo, Antonio, Guarini, Anna, Foà, Robin, and Del Giudice, Ilaria

Subjects
Adenine, clonal evolution, Leukemia, Lymphocytic, Chronic, B-Cell, NO, ibrutinib, TP53, clonal evolution, chronic lymphocytic leukemia, next-generations sequencing, Piperidines, ibrutinib, Chronic Lymphocytic Leukemia, TP53, Humans, chronic lymphocytic leukemia, Tumor Suppressor Protein p53, Letters to the Editor
Published
2022

37. Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia

Author

Fazio, Francesca, primary, Cunsolo, Gabriella, additional, Mancini, Francesca, additional, De Propris, Maria Stefania, additional, Piciocchi, Alfonso, additional, Arena, Valentina, additional, Messina, Monica, additional, Ansuinelli, Michela, additional, Taherinasab, Akram Taherinasab, additional, Apicella, Valerio, additional, Vitale, Antonella, additional, Chiaretti, Sabina, additional, Guarini, Anna, additional, del Giudice, Ilaria, additional, and Foà, Robin, additional

Published
2022
Full Text
View/download PDF

38. Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study

Author

Mauro, Francesca Romana, primary, Paoloni, Francesca, additional, Molica, Stefano, additional, Reda, Gianluigi, additional, Trentin, Livio, additional, Sportoletti, Paolo, additional, Marchetti, Monia, additional, Pietrasanta, Daniela, additional, Marasca, Roberto, additional, Gaidano, Gianluca, additional, Coscia, Marta, additional, Stelitano, Caterina, additional, Mannina, Donato, additional, Di Renzo, Nicola Di, additional, Ilariucci, Fiorella, additional, Liberati, Anna Marina, additional, Orsucci, Lorella, additional, Re, Francesca, additional, Tani, Monica, additional, Musuraca, Gerardo, additional, Gottardi, Daniela, additional, Zinzani, Pier Luigi, additional, Gozzetti, Alessandro, additional, Molinari, Annalia, additional, Gentile, Massimo, additional, Chiarenza, Annalisa, additional, Laurenti, Luca, additional, Varettoni, Marzia, additional, Ibatici, Adalberto, additional, Murru, Roberta, additional, Ruocco, Valeria, additional, Del Giudice, Ilaria Del, additional, De Propris, Maria Stefania De, additional, Della Starza, Irene Della, additional, Raponi, Sara, additional, Nanni, Mauro, additional, Fazi, Paola, additional, Neri, Antonino, additional, Guarini, Anna, additional, Rigolin, Gian Matteo, additional, Piciocchi, Alfonso, additional, Cuneo, Antonio, additional, and Foà, Robin, additional

Published
2021
Full Text
View/download PDF

39. A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Author

Zaccaria, Gian Maria, primary, Ferrero, Simone, additional, Hoster, Eva, additional, Passera, Roberto, additional, Evangelista, Andrea, additional, Genuardi, Elisa, additional, Drandi, Daniela, additional, Ghislieri, Marco, additional, Barbero, Daniela, additional, Del Giudice, Ilaria, additional, Tani, Monica, additional, Moia, Riccardo, additional, Volpetti, Stefano, additional, Cabras, Maria Giuseppina, additional, Di Renzo, Nicola, additional, Merli, Francesco, additional, Vallisa, Daniele, additional, Spina, Michele, additional, Pascarella, Anna, additional, Latte, Giancarlo, additional, Patti, Caterina, additional, Fabbri, Alberto, additional, Guarini, Attilio, additional, Vitolo, Umberto, additional, Hermine, Olivier, additional, Kluin-Nelemans, Hanneke C, additional, Cortelazzo, Sergio, additional, Dreyling, Martin, additional, and Ladetto, Marco, additional

Published
2021
Full Text
View/download PDF

40. Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments

Author

Del Giudice, Ilaria, Marinelli, Marilisa, Wang, Jiguang, Bonina, Silvia, Messina, Monica, Chiaretti, Sabina, Ilari, Caterina, Cafforio, Luciana, Raponi, Sara, Mauro, Francesca R., Di Maio, Valeria, De Propris, Maria S., Nanni, Mauro, Ciardullo, Carmela, Rossi, Davide, Gaidano, Gianluca, Guarini, Anna, Rabadan, Raul, and Foà, Robin

Published
2016
Full Text
View/download PDF

42. A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Author

Ladetto, Marco, primary, Ferrero, Simone, additional, Del Giudice, Ilaria, additional, Galimberti, Sara, additional, Gattei, Valter, additional, Marcheselli, Luigi, additional, Mantoan, Barbara, additional, Genuardi, Elisa, additional, Alessandria, Beatrice, additional, Ferrante, Martina, additional, Dogliotti, Irene, additional, Della Starza, Irene, additional, De Novi, Lucia Anna, additional, Cavalli, Marzia, additional, Grassi, Susanna, additional, Ciabatti, Elena, additional, Guerrini, Francesca, additional, Bomben, Riccardo, additional, Degan, Massimo, additional, Zaina, Eva, additional, Perrone, Tommasina, additional, Petrini, Mario, additional, Re, Francesca, additional, Olivieri, Attilio, additional, Usai, Sara Veronica, additional, Mannina, Donato, additional, Falini, Brunangelo, additional, Rota Scalabrini, Delia, additional, Stefani, Pietro Maria, additional, Ballerini, Filippo, additional, Federico, Massimo, additional, and Luminari, Stefano, additional

Published
2021
Full Text
View/download PDF

43. Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia

Author

Cafforio, Luciana, primary, Raponi, Sara, additional, Cappelli, Luca Vincenzo, additional, Ilari, Caterina, additional, Soscia, Roberta, additional, De Propris, Maria Stefania, additional, Mariglia, Paola, additional, Rigolin, Gian Matteo, additional, Bardi, Antonella, additional, Peragine, Nadia, additional, Piciocchi, Alfonso, additional, Arena, Valentina, additional, Mauro, Francesca Romana, additional, Cuneo, Antonio, additional, Guarini, Anna, additional, Foa, Robin, additional, and Del Giudice, Ilaria, additional

Published
2021
Full Text
View/download PDF

44. COMPLEX KARYOTYPE IN UNFIT PATIENTS WITH CLL TREATED WITH IBRUTINIB AND RITUXIMAB. THE GIMEMA LLC1114 PHASE 2 STUDY

Author

Rigolin, Gian Matteo, primary, Del Giudice, Ilaria, additional, Bardi, Maria Antonella, additional, Melandri, Aurora, additional, García-Jacobo, Rocio Edith, additional, Cura, Francesca, additional, Raponi, Sara, additional, Ilari, Caterina, additional, Cafforio, Luciana, additional, Piciocchi, Alfonso, additional, Arena, Valentina, additional, Reda, Gianluigi, additional, Albano, Francesco, additional, Molica, Stefano, additional, Sportoletti, Paolo, additional, Trentin, Livio, additional, Marchetti, Monia, additional, Nanni, Mauro, additional, Peragine, Nadia, additional, Mariglia, Paola, additional, Vignetti, Marco, additional, Guarini, Anna Rita, additional, Mauro, Francesca Romana, additional, Foà, Robin, additional, and Cuneo, Antonio, additional

Published
2021
Full Text
View/download PDF

45. Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network

Author

Mantoan, Barbara, primary, Genuardi, Elisa, additional, Ferrante, Martina, additional, Della Starza, Irene, additional, Ciabatti, Elena, additional, Grassi, Susanna, additional, De Novi, Lucia Anna, additional, Cavalli, Marzia, additional, Mannu, Claudia, additional, Gazzola, Anna, additional, Bomben, Riccardo, additional, Degan, Massimo, additional, Alessandria, Beatrice, additional, Pott, Christiane, additional, Delfau-Larue, Marie-Hélène, additional, García-Sanz, Ramon, additional, Agostinelli, Claudio, additional, Gattei, Valter, additional, Galimberti, Sara, additional, Del Giudice, Ilaria, additional, Gaidano, Gianluca, additional, Ladetto, Marco, additional, Ferrero, Simone, additional, and Drandi, Daniela, additional

Published
2021
Full Text
View/download PDF

47. High Basal Maximal Standardized Uptake Value (SUVmax) in Follicular Lymphoma Identifies Patients with a Low Risk of Long-Term Relapse

Author

Assanto, Giovanni Manfredi, primary, Ciotti, Giulia, additional, Brescini, Mattia, additional, De Luca, Maria Lucia, additional, Annechini, Giorgia, additional, D’Elia, Gianna Maria, additional, Agrippino, Roberta, additional, Del Giudice, Ilaria, additional, Martelli, Maurizio, additional, Chiaravalloti, Agostino, additional, and Pulsoni, Alessandro, additional

Published
2021
Full Text
View/download PDF

48. CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Author

Bomben, Riccardo, Zucchetto, Antonella, Laureana, Roberta, Chiarenza, Annalisa, Olivieri, Jacopo, Tissino, Erika, Rossi, Francesca, Vit, Filippo, Bittolo, Tamara, Papotti, Robel, Pozzo, Federico, Gaglio, Annalisa, Degan, Massimo, Polesel, Jerry, Marasca, Roberto, Reda, Gianluigi, Visentin, Andrea, Moia, Riccardo, Innocenti, Idanna, Vitale, Candida, Murru, Roberta, Varettoni, Marzia, Tafuri, Agostino, Zaja, Francesco, Postorino, Massimiliano, Martino, Enrica Antonia, Condolucci, Adalgisa, Rossi, Davide, Cuneo, Antonio, Di Raimondo, Francesco, Sportoletti, Paolo, Del Giudice, Ilaria, Foa, Robin, Mauro, Francesca Romana, Coscia, Marta, Laurenti, Luca, Gaidano, Gianluca, Trentin, Livio, Del Principe, Maria Ilaria, Gentile, Massimo, and Gattei, Valter

Published
2023
Full Text
View/download PDF

49. Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Author

Pulsoni, Alessandro, Tosti, Maria Elena, Ferrero, Simone, Luminari, Stefano, Dondi, Alessandra, Liberati, Anna Marina, Cenfra, Natalia, Renzi, Daniela, Zanni, Manuela, Boccomini, Carola, Ferreri, Andrés José María, Rattotti, Sara, Zilioli, Vittorio Ruggero, Bernuzzi, Patrizia, Bolis, Silvia, Musuraca, Gerardo, Nassi, Luca, Perrone, Tommasina, Stelitano, Caterina, Anastasia, Antonella, Corradini, Paolo, Partesotti, Giovanni, Re, Francesca, Cencini, Emanuele, Mannarella, Clara, Mannina, Donato, Molinari, Anna Lia, Tani, Monica, Annechini, Giorgia, Assanto, Giovanni Manfredi, Grapulin, Lavinia, Guarini, Anna, Cavalli, Marzia, De Novi, Lucia Anna, Bomben, Riccardo, Ciabatti, Elena, Mantoan, Barbara, Drandi, Daniela, Della Starza, Irene, Arcaini, Luca, Ricardi, Umberto, Gattei, Valter, Galimberti, Sara, Ladetto, Marco, Foà, Robin, and Del Giudice, Ilaria

Published
2023
Full Text
View/download PDF

50. 36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Author

Mauro, Francesca Romana, Della Starza, Irene, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Gaidano, Gianluca, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Stelitano, Caterina, Mannina, Donato, Ilariucci, Fiorella, Massaia, Massimo, Rigolin, Gian Matteo, Scarfo, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Belsito Patrizi, Valeria, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pepe, Sara, Andriola, Costanza, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, and Foà, Robin

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results